FDA Signals Potential Expansion of Testosterone Therapy Indications to Include Low Libido in Women

The U.S. Food and Drug Administration is reportedly considering an expansion of approved uses for testosterone therapy, potentially opening the door to treatments aimed at addressing low libido, particularly in postmenopausal women. The regulatory shift could reshape a market long dominated by off-label prescribing and reignite debate over hormone therapy safety, efficacy, and access.

The FDA’s apparent openness to expanding testosterone therapy marks a significant development in a field that has operated largely in a regulatory gray zone for decades. Although men have had access to approved testosterone products for conditions such as hypogonadism since the 1950s, no formulation has ever been approved in the U.S. for female patients. Despite this, clinicians routinely prescribe male-formulated testosterone at fractional doses to women experiencing low libido, particularly those in menopause or post-menopause. The International Society for the Study of Women’s Sexual Health and The Endocrine Society have both issued guidelines supporting the practice, citing randomized controlled trials showing modest but measurable improvements in sexual desire and satisfaction.

The agency’s previous reluctance stems in part from the 2004 rejection of Intrinsa, a testosterone patch developed by Procter & Gamble specifically for women with HSDD. At the time, advisors raised concerns about long-term cardiovascular and breast cancer risks. Since then, only two drugs—flibanserin (Addyi) and bremelanotide (Vyleesi)—have received FDA approval for female sexual dysfunction, and both have faced commercial struggles and criticism over modest efficacy. An expanded testosterone indication could substantially alter the treatment landscape, which affects an estimated 10% of adult women in the U.S. who report distressing low sexual desire.

Beyond the testosterone discussion, the broader biotech landscape continues to evolve rapidly. New research is probing why GLP-1 receptor agonists—the class that includes blockbuster drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound—affect appetite, metabolism, and potentially addictive behaviors so profoundly, with some scientists questioning established theories about the hormone’s evolutionary role. Separately, a potential pancreatic cancer breakthrough has drawn attention given the disease’s dismal five-year survival rate of roughly 13%, one of the lowest among major cancers. Any therapeutic advance in this area carries outsized significance for a patient population with historically few effective options.